Ownership Submission
|
FORM 4
|
|
Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
OMB APPROVAL
|
|
OMB Number:3235-0287Expires:January 31, 2005Estimated average burden hours per response...0.5
|
|
|
1. Name and Address of Reporting Person *
|
|
Bhat Laxminarayan
|
|
2. Issuer Name and Ticker or Trading Symbol
REVIVA PHARMACEUTICALS HOLDINGS, INC. [RVPH]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
__X__ Director
|
_____ 10% Owner
|
|
_____ Officer (give title below)
|
_____ Other (specify below)
|
|
President and CEO /
|
|
|
(Last)
|
(First)
|
(Middle)
|
|
C/O REVIVA PHARMACEUTICALS HOLDINGS, INC , 10080 N. WOLFE RD., SUITE SW3-200
|
|
3. Date of Earliest Transaction (Month/Day/Year)
|
(Street)
|
|
CUPERTINO
|
CA
|
95014
|
|
4. If Amendment, Date Original Filed(Month/Day/Year)
|
6. Individual or Join/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
|
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
|
|
1.Title of Security
|
2. Transaction Date (Month/Day/Year)
|
2A. Deemed Execution Date, if any (Month/Day/Year)
|
3. Transaction Code
|
4. Securities Acquired (A) or Disposed of (D)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
|
6. Ownership Form: Direct (D) or Indirect (I)
|
7. Nature of Indirect Beneficial Ownership
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
(e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
|
2. Conversion or Exercise Price of Derivative Security
|
3. Transaction Date (Month/Day/Year)
|
3A. Deemed Execution Date, if any (Month/Day/Year)
|
4. Transaction Code
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
|
8. Price of Derivative Security
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
|
11. Nature of Indirect Beneficial Ownership
|
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expriation Date
|
Title
|
Amount or Number of Shares
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
|
Director
|
10% Owner
|
Officer
|
Other
|
Bhat Laxminarayan
C/O REVIVA PHARMACEUTICALS HOLDINGS, INC
10080 N. WOLFE RD., SUITE SW3-200
CUPERTINO, CA95014
|
X
|
X
|
President and CEO
|
|
Signatures
|
/s/ Narayan Prabhu, Attorney-in-Fact
|
2024-09-17
|
|
**Signature of Reporting Person
|
Date
|
Explanation of Responses:
|
(*)
|
If the form is filed by more than one reporting person, see Instruction 5(b)(v).
|
|
(**)
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
|
(1)
|
Represents an option award granted to Dr. Laxminarayan Bhat, the Issuer's President and Chief Executive Officer (the "Reporting Person"), by the Issuer's compensation committee (the "Compensation Committee") on September 15, 2024 (the "Grant Date") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). On the Grant Date, the Compensation Committee determined the amount of incentive bonus earned by Dr. Bhat for 2023 and determined that the Issuer would pay the incentive bonus in the form of fully vested options in lieu of cash payment. The exercise price of the option award is based on the closing price of the Issuer's common stock on September 13, 2024, in accordance with the terms of the 2020 Plan.
|
|
(2)
|
Represents an option award granted to Ms. Seema Bhat, the Issuer's Vice President for Program & Portfolio Management and the spouse of the Reporting Person, by the Compensation Committee on September 15, 2024, in accordance with the terms of the 2020 Plan. On the Grant Date, the Compensation Committee determined the amount of incentive bonus earned by Ms. Bhat for 2023 and determined that the Issuer would pay the incentive bonus in the form of fully vested options in lieu of cash payment. The exercise price of the option award is based on the closing price of the Issuer's common stock on September 13, 2024, in accordance with the terms of the 2020 Plan.
|
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
